Aligos Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview

Aligos Therapeutics

31/10/2022 20:23

* Aligos Therapeutics Inc  ALGS.OQ   ALGS.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
2. 
    * The South San Francisco California-based  company is
expected to
report  a 51.2% decrease in revenue to $750 thousand from $1.54
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aligos Therapeutics
Inc
is for a loss of 58 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $2.25​, above​ its last closing price
of $1.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.62       -0.67      -0.47     Beat    29.5
 Mar. 31 2022  -0.74       -0.73      -0.84     Missed  -15.5
 Dec. 31 2021  -0.88       -0.83      -0.89     Missed  -7.5​
 Sep. 30 2021  -0.81       -0.81      -0.78     Beat    4.2
 ​​Jun.        -0.81       -0.81      -0.79     Beat    2.1
 30 2021                                                
 Mar. 31 2021  -0.90       -0.90      -0.74     Beat    17.8​
 Dec. 31 2020  -0.85       -0.82      -1.09     Missed  -32.1
 Sep. 30 2020  -0.78       -0.78      -11.00    Missed  -1,310
                                                        .3
 This summary was machine generated October 31 at 20:23 GMT.  All
figures in US dollars  unless otherwise stated